

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/IF0733C3A648EN.html>

Date: April 2022

Pages: 160

Price: US\$ 2,000.00 (Single User License)

ID: IF0733C3A648EN

Abstracts

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Thrombocytopenic Purpura - Drugs In Development, 2022, provides an overview of the Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline landscape.

Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role in normal blood clotting. Symptoms include blood in urine or stools, fatigue, spontaneous bleeding from nose and superficial bleeding into skin that appears as a rash of pinpoint sized reddish purple spots, usually on lower legs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Thrombocytopenic Purpura - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Hematological Disorders), complete with analysis by stage of development,

drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 5, 11, 14, 3, 1 and 7 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Hematological Disorders).

The pipeline guide reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Idiopathic Thrombocytopenic Purpura (Hematological Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Idiopathic Thrombocytopenic Purpura (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Hematological Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Hematological Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) -

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) -

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) -

Companies Involved in Therapeutics Development

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Drug Profiles

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) -

Discontinued Products

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones

Featured News & Press Releases

Jul 23, 2021: Borui's new drug Zebetuzumab injection have been approved for clinical trials

Jul 14, 2021: New TAVALISSE data analyses to be presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress

Jun 29, 2021: Hengrui Pharmaceutical provides double guarantee of efficacy and safety for ITP treatment

Jun 01, 2021: Sobi at EHA virtual congress 2021: focus on use Doptelet (avatrombopag) in chronic immune thrombocytopenia

May 28, 2021: The application for clinical trial of Zuberitamab biological product of Borui biotechnology have been accepted successively

May 12, 2021: New data on rilzabrutinib to be featured at EHA 2021 Congress highlight Sanofi's ongoing commitment to rare blood disorders

Mar 12, 2021: First patient dosed in phase 3 study with avatrombopag for treatment of ITP in children

Jun 13, 2019: Rigel to present two posters highlighting Fostamatinib at the 24th Congress of the European Hematology Association

May 16, 2019: Rigel enrolls first patient in phase 3 clinical trial of Fostamatinib Disodium Hexahydrate in warm autoimmune hemolytic anemia

Feb 11, 2019: Scottish Medicine Consortium, following an abbreviated submission has accepted romiplostim (Nplate) for restricted use within NHSScotland

Dec 03, 2018: argenx provides detailed data from phase 2 clinical trial of efgartigimod in immune thrombocytopenia

Dec 02, 2018: Real-world data show Novartis drug Revolade improves outcomes for ITP patients compared to other second-line therapies

Oct 19, 2018: Principia Biopharma announces PRN1008 receives orphan-drug designation from FDA for treatment of immune thrombocytopenic purpura

Jul 31, 2018: Kyowa Hakko Kirin submits application for additional indication for Romiplostim (Recombinant) for aplastic anemia in Japan

Jan 04, 2018: Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by 3SBio Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Amgen Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Argenx SE, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by BeiGene Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Beijing Tide Pharmaceutical Co Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Biogen Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Biotest AG, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by BioXpress Therapeutics SA, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Clover Biopharmaceuticals Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Cour Pharmaceuticals Development Co Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by GC Pharma, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Generium, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Genosco Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by GlaxoSmithKline Plc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by HanAll Biopharma Co Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Hutchison MediPharma Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Iltoo Pharma, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by InnoCare Pharma Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by KM Biologics Co Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Novartis AG, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Oak Hill Bio Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pfizer Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pharmagenesis Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pharmaprxaxis, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by PlateletBio, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Principia Biopharma Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Qilu Pharmaceutical Co Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Rigel Pharmaceuticals Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Shandong Quangang Pharmaceutical Co Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline

by Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline
by Sichuan Kelun Pharmaceutical Co Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline
by Simcere Pharmaceutical Group Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline
by Swedish Orphan Biovitrum AB, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline
by Taiho Pharmaceutical Co Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline
by Takeda Pharmaceutical Co Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline
by UCB SA, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline
by Zhejiang Hisun Pharmaceutical Co Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline
by Zhengda Tianqing Pharmaceutical Group Co Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant
Projects, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant
Projects, 2022 (Contd..1)
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) -
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/IF0733C3A648EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IF0733C3A648EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970